A new treatment being developed to reduce chronic drooling

North West pharmaceutical company Proveca Limited has reached a key agreement with the European Medicines Agency (EMA) that will enable the development of a new drug designed for children and young people.   

This is Glycopyrronium – a drug designed to combat chronic pathological drooling (sialorrhoea) in children. Children living with motor or neurological disorders, such as cerebral palsy, are often unable to effectively swallow the saliva they produce resulting in unavoidable chronic drooling. Glycopyrronium will help to reduce this unintentional and disabling loss of saliva. 

For more information please visit http://www.proveca.co.uk/news/proveca-reaches-milestone-in-development-of-innovative-drug